Recent Updates
Recently added Catalysts

AG221

Phase 1

Healthy Volunteers | Small molecule | Other |Agios Pharmaceuticals, Inc.|Last Updated: Dec 14, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02218346Food Effect Study of AG-221 in Healthy Male SubjectsPHASE1 COMPLETED 30Aug 1, 2014Mar 1, 2015Dec 14, 20151 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Pharmacokinetic (PK) profile of AG-221
Blood samples will be drawn prior to the single-dose administration of AG-221 (within 30 minutes) on Day 1 of each period, and at the following time points post dose: 1, 2, 3, 4, 6, 9, 12, 18, 24, 48, 96, 168, 240, 336, and 504 hours.

Serial blood sampling at specified time points for determination of plasma concentration-time profiles and PK parameters of AG-221.

Incidence of adverse events
105 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Treatment A (unfed)ACTIVE_COMPARATORTreatment A: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, following a 10-hour overnight fast.
Treatment B (fed)ACTIVE_COMPARATORTreatment B: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
Interventions
NameTypeDescription
AG221DRUGAG221 in fed and fasted conditions
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 56 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy adult male subjects 18 to 56 years of age, inclusive, at Screening. 2. Subjects who are able to understand and sign informed consent prior to the conduct of any protocol-specific screening procedures. 3. Subjects must be willing and able to complete all study assessme...

Countries:United States
Unlock Eligibility Criteria